Praxis Precision Medicines Inc. Common Stock (PRAX)

FairStock Score: 16/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at Praxis Precision Medicines and I see a clinical-stage biotechnology company, not a business I can value on earnings. It is developing CNS therapies through its Cerebrum and Solidus platforms, with ulixacaltamide as a lead candidate. Revenue is negligible: in fiscal 2024, the period ended 2024-12-31, revenue was $8.6 million, up from $2.4 million in fiscal 2023, period ended 2023-12-31; fiscal 2025 revenue was N/A. Losses are widening: fiscal 2023 net loss $123.3 million, fiscal 2024 net loss $182.8 million, and fiscal 2025 net loss $303.3 million. In fiscal Q2 2026, the quarter ended 2026-06-30, net loss was $83.7 million and diluted EPS was -$2.87. Trailing free cash flow is -$306.2 million, a -4.5% FCF yield on a $6.8 billion market cap. The balance sheet has no debt, D/E 0.00, but no debt does not equal safety when cash burn is large and future financing likely. FairStock's P/E is -18.76, P/B is 5.07 at the 2026-10-13 close of $243.34, and its Piotroski F-Score is 1/9, so the market is paying a rich price for pipeline hope. The moat? I see none yet. An experimental CNS pipeline can be valuable if data are strong, but until approvals or partnerships produce cash, it is a speculative option. FairStock score 16/100 and no Lynch category because of losses in each of the last four years. I would demand a much larger margin of safety than this price offers.

In plain English: Praxis Precision Medicines is an early-stage drug developer testing experimental medicines for brain and nervous system disorders. It has almost no product sales and has lost money every recent year, with losses growing. At $243.34, the stock price reflects big future hopes rather than today's business results, so it looks expensive and very risky compared with its current numbers.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer